Volumen: 13 # Number : 2
Publication Date : Mayo - Agosto Year: 2009
Authors: José M. Ceresetto
Abstract: Venous thromboembolism is the most common
preventable cause of death among hospitalised patients and
a serious health-care problem all around the world.
Parenteral prophylaxis had been the gold standard until
now but new antithrombotic oral agents are under
investigation and will soon be available in Argentina.
Dabigatran Etexilate is an oral antithrombinic with efficacy
and safety similar to enoxaparin. It´s drawbacks are the
need for dose adjustment and the absence of an antidote.
Rivaroxaban is an oral, direct Factor Xa inhibitor that has
been superior to enoxaparin in four prophylaxis trials but
it also has no antidote. Both drugs are started after surgery,
they don’t produce thrombocytopenia and avoid the
subcutaneous injection. Their limitations are the high cost
of the drug and the scarse clinical experience with these
new agents. Only time will confirm that these better drugs
result in a better DVT prophylaxis.
Key words: Thromboprophylaxis. New anticoagulants.
Oral vs parenteral.
Pages : 53-67
|
